文献速递血栓与止血贫血与红细胞疾病

SARS-CoV-2疫苗接种后自身免疫及补体介导的血液病复发

Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination.
PubMed 文献 · Blood Adv · 2021-01-01

该文报告了2021年1月至3月在华盛顿大学医学中心与西雅图癌症护理联盟观察到的3例SARS-CoV-2疫苗接种后自身免疫或补体介导的血液病复发,包括2例自身免疫病(ITP和AvWD/获得性血友病A)及1例补体病(PNH)。文中首次报告AvWD/获得性血友病A病例及无补体抑制情况下PNH加重,并基于经验提出对基础自身免疫及补体介导血液病患者监测与风险评估的考虑。

要点

  • SARS-CoV-2疫苗接种后可出现原有自身免疫性血液病复发。
  • 本文首次报告接种后AvWD/获得性血友病A及无补体抑制的PNH加重。
  • 原有ITP患者血小板减少可随每剂疫苗接种序贯性加重。

核心结论

  • SARS-CoV-2疫苗接种可导致原有自身免疫及补体介导的血液病复发,包括ITP、AvWD/获得性血友病A和PNH。
  • 对基础自身免疫及补体介导血液病患者需考虑疫苗接种后监测与风险评估。

研究设计与样本

  • 研究为病例系列,于2021年1月至3月在华盛顿大学医学中心与西雅图癌症护理联盟识别3例接种后复发病例。

主要发现

  • 报告2例自身免疫病复发(ITP和AvWD/获得性血友病A)及1例补体病复发(PNH)。
  • 报告首例已知AvWD/获得性血友病A病例及首例无补体抑制情况下SARS-CoV-2疫苗接种后PNH加重。
  • 原有ITP患者血小板减少可随每剂疫苗接种序贯性加重。

临床怎么用

  • 对原有自身免疫及补体介导血液病患者,接种SARS-CoV-2疫苗后应监测疾病复发。
  • 基于本文经验考虑对上述患者进行风险评估与监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A variety of autoimmune disorders have been reported after viral illnesses and specific vaccinations. Cases of de novo immune thrombocytopenia (ITP) have been reported after SARS-CoV-2 vaccination, although its effect on preexisting ITP has not been well characterized. In addition, although COVID-19 has been associated with complement dysregulation, the effect of SARS-CoV-2 vaccination on preexisting complementopathies is poorly understood. We sought to better understand SARS-CoV-2 vaccine-induced recurrence of autoimmune- and complement-mediated hematologic conditions. Three illustrative cases were identified at the University of Washington Medical Center and the Seattle Cancer Care Alliance from January through March 2021. We describe the recrudescence of 2 autoimmune conditions (ITP and acquired von Willebrand Disease [AvWD]/acquired hemophilia A) and 1 complementopathy (paroxysmal nocturnal hemoglobinuria [PNH]). We report the first known case of AvWD/acquired hemophilia A, and describe the first PNH exacerbation in the absence of complement inhibition after SARS-CoV-2 vaccination. Although SARS-CoV-2 vaccine-induced ITP is a known concern, our case clearly depicts how thrombocytopenia in the setting of preexisting ITP can sequentially worsen with each vaccine dose. Based on our experiences and these examples, we provide considerations for how to monitor and assess risk in patients with underlying autoimmune- and complement-mediated hematologic conditions.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Portuguese AJ, Sunga C, Kruse-Jarres R, et al. Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination. Blood Adv. 2021. PMID: 34255033. doi:10.1182/bloodadvances.2021004957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。